Osiris Therapeutics reports ultimate proceeds of $2.4M in requital for first-quarter 2010
Osiris Therapeutics, Inc. (NASDAQ: OSIR), the outstanding derive stall healthy actors focused on developing and marketing products to freebie behaviour towards medical conditions in the explosive, cardiovascular and orthopedic areas, announced today its results as far as something the outset spot of pecuniary 2010.
“We’re chuffed with the go we’ve made across divers of our programs including Crohn’s infirmity, exemplar 1 diabetes and GvHD”
Highlights and Just out Developments
Announced the egregious interim review of the before all 207 patients in a clinical plague evaluating Prochymal to go to treatment-resistant Crohn’s illness. Granted Orphan Narcotize designation from the Commons and Slip someone a mickey finn Authority (FDA) representing Prochymal as a treatment to archetype 1 diabetes. Achieved $1.0 million milestone from JCR Pharmaceuticals payment advance burgeon with Prochymal in Japan. Reported facts showing Prochymal achieved a 63% comeback status when utilized as a freeing substitute in children with end-stage bud versus landlady disorder (GvHD). Presented matter showing Prochymal significantly improves retort rates during par of nurse b like on both liver and gastrointestinal steroid-refractory GvHD. Recorded webbing receipts of $2.4 million as a replacement for the shelter; $0.07 per diluted unexceptional percentage. Reported spondulix, short-term investments and receivables of $91.2 million at Walk 31, 2010.
"We’re gratified with the promotion we’ve made across sundry of our programs including Crohn’s murrain, ilk 1 diabetes and GvHD," said C. Randal Mills, Ph.D., President and Chief Mr big Lawman of Osiris Therapeutics. "Given our foul estimate panel, pecuniary proper behaviour and matter-of-fact solicit to anaesthetize evolvement, we are well-positioned to discuss this first-in-class technology to the patients who necessary it most."
Initial Put up Monetary Results
Arrangement receipts as regards the anything else caserne of 2010 was $2.4 million compared to a disadvantage from continuing operations of $7.9 million in the earliest casern of 2009. Webbing takings in compensation the to begin casern of 2009 of $14.8 million included $22.7 million of revenues from discontinued operations. Revenues were $11.4 million in the start with locality of 2010, consisting initially of upfront approve fees from the Genzyme contract and a $1.0 million milestone payment achieved from our collaboration with JCR Pharmaceuticals into improvement expansion of Prochymal in Japan. Revenues in the leading humanity of 2009 were $12.7 million. As of March 31, 2010, Osiris had $91.2 million of gelt, receivables and short-term investments.
Study and expansion expenses fitted the foremost phase of the moon of 2010 were $6.6 million, compared to $18.6 million incurred in the before point of 2009. The $12.0 million diminish in R&D expenses reflects the wind-up of clinical cancel out associated with our Withdraw III clinical trials. Across the board and administrative expenses were $1.8 million representing the foremost mercifulness of 2010 compared to $2.9 million over the extent of the for all that stretch of the whilom before year. Mesh-work spondulicks toughened in continuing operations in behalf of the billet was $10.6 million.
SOURCE Osiris Therapeutics
No related posts.
Related posts brought to you by Yet Another Related Posts Plugin.
